ArticleACR open rheumatology2026

Effectiveness of Canakinumab for First-Line Steroid-Free Treatment in Systemic-Onset Juvenile Idiopathic Arthritis and Juvenile Still Disease.

Gerd Horneff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.